EUVIMEDEUVIMED entdecken
Open Access

Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment

Pattareeya Yottasan, Tifany Chu, Parth D Chhetri, Onur Cil

Translational Research · 2024

DOI: 10.1016/j.trsl.2023.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2024. Verfasst von Pattareeya Yottasan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, San Francisco, 513 Parnassus Avenue, HSE 1244, San Francisco, CA, 94143, United States. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant, Cysts. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institutes of Health, University of Kansas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ADPKD is characterized by progressive cyst formation and enlargement leading to kidney failure. Tolvaptan is currently the only FDA-approved treatment for ADPKD; however, it can cause serious adverse effects including hepatotoxicity. There remains an unmet clinical need for effective and safe treatments for ADPKD. The extracellular Ca2+-sensing receptor (CaSR) is a regulator of epithelial ion transport. FDA-approved CaSR activator cinacalcet can reduce cAMP-induced Cl- and fluid secretion in various epithelial cells by activating phosphodiesterases (PDE) that hydrolyze cAMP. Since elevated cAMP is a key mechanism of ADPKD progression by promoting cell proliferation, cyst formation and enlargement (via Cl- and fluid secretion), here we tested efficacy of cinacalcet in cell and animal models of ADPKD. Cinacalcet treatment reduced cAMP-induced Cl- secretion and CFTR activity in MDCK cells as suggested by ∼70 % lower short-circuit current (Isc) changes in response to forskolin and CFTRinh-172, respectively. Cinacalcet treatment inhibited forskolin-induced cAMP elevation by 60 % in MDCK cells, and its effect was completely reversed by IBMX (PDE inhibitor). In MDCK cells treated with forskolin, cinacalcet treatment concentration-dependently reduced cell proliferation, cyst formation and cyst enlargement by up to 50 % without affecting cell viability. Cinacalcet treatment (20 mg/kg/day for 7 days, subcutaneous) reduced renal cyst index in a mouse model of ADPKD (Pkd1flox/flox;Ksp-Cre) by 20 %. Lastly, cinacalcet treatment reduced cyst enlargement and cell proliferation in human ADPKD cells by 60 %. Considering its efficacy as shown here, and favorable safety profile including extensive post-approval data, cinacalcet can be repurposed as a novel ADPKD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Kidney, Autosomal DominantCystsMiceAnimalsHumansCinacalcetReceptors, Calcium-SensingColforsinDrug RepositioningCells, CulturedKidney

Stichwörter der Autor:innen

CiliopathyDrug repurposingPolycystic kidney disease

Substanzen

CinacalcetReceptors, Calcium-SensingColforsin

Autor:innen und Institutionen

  • Department of Pediatrics, University of California, San Francisco, 513 Parnassus Avenue, HSE 1244, San Francisco, CA, 94143, United States.
  • Department of Pediatrics, University of California, San Francisco, 513 Parnassus Avenue, HSE 1244, San Francisco, CA, 94143, United States. Electronic address: onur.cil@ucsf.edu.

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health
  • University of Kansas
  • University of Maryland

Zitieren

APA

Yottasan, P., Chu, T., Chhetri, P. D., & Cil, O. (2024). Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment. Translational Research. https://doi.org/10.1016/j.trsl.2023.10.005

Vancouver

Yottasan P, Chu T, Chhetri PD, Cil O. Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment. Translational Research. 2024. doi:10.1016/j.trsl.2023.10.005

BibTeX
@article{Yottasan2024,
  author = {Yottasan, Pattareeya and Chu, Tifany and Chhetri, Parth D and Cil, Onur},
  title = {Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment},
  journal = {Translational Research},
  year = {2024},
  doi = {10.1016/j.trsl.2023.10.005}
}
Kostenlos starten →